• June 16-19, 2025
  • Boston Convention & Exhibition Center

Sessions

Loading

Approaching the Tipping Point: The Emergence of Allogeneic Cell Therapy for Oncology

Thursday, June 06, 2024
Breakout Session
Oncology
31AB
While autologous cell therapies have delivered impressive results, manufacturing is expensive, highly variable, and difficult to scale. They also add logistical hurdles at treatment centers and require space for apheresis and transport of individual patient material, resulting in products often not reaching patients in need. Allogeneic (allo) cell therapies, including CAR-T, are a long-awaited next-generation option addressing many of these challenges. Here, T cells derived from healthy donors as opposed to heavily pretreated patients result in theoretically higher quality products, which may ultimately correlate with superior clinical effect. This discussion will explore the promise of allo cell therapies to broaden patient access, lower costs, and increase reliability and scalability.
Moderator
George Eastwood
Board Chair/Interim Executive Director
The Emily Whitehead Foundation
Speakers
Cokey Nguyen, PhD
Chief Scientific and Technical Officer
Atara Biotherapeutics
Abigail Jenkins
Former President & CEO
Gamida Cell
P.K. Morrow, MD, FACP
Senior Vice President and Head of Oncology Therapeutic Area Unit
Takeda
Kristin Yarema, PhD
President & CEO
Poseida Therapeutics
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS